Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

This study is a prospective, multicenter, open-label umbrella clinical study planned to enroll 126 subjects with acute myeloid leukemia/myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. Subjects eligible for enrollment were grouped based on the results of the initial myeloid genomic second-generation sequencing, and were given different regimens of maintenance therapy, with the aim of evaluating the efficacy and safety of the maintenance regimen.

Trial Details

NCT ID
NCT06972641
Phase
PHASE2 / PHASE3
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Decitabine
  • Sorafenib (BAY-43-9006),giritinib
  • Avastinib
  • Venetoclax;Selenisol
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\) Age 14-75 years and gender; (2) Initial diagnosis, pre-transplant myelogenetic second-generation sequencing data refinement; 3)ARM1: TP53 mutat…
  • Aspartate aminotransferase (AST) ≤ 3 times ULN (upper limit of normal, ULN);
  • Alanine aminotransferase (ALT) ≤ 3x ULN;
  • Total serum bilirubin ≤ 1.5 times the upper limit of normal ULN unless the patient has documented Gilbert's syndrome; patients with Gilbert's syndr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →